New review below [1].
There may be some who are still under the impression that ADT offers protection against Covid-19.
Unfortunately ...
Conclusions
"A number of studies have reported the outcomes of patients receiving ADT for PC who developed SARS-CoV-2 infection, but their conflicting findings concerning the protective role of ADT in terms of infection susceptibility and severity can be explained by considering their methodological differences and, mainly, their failure to capture information that critically contributes to infection outcomes, such as age, co-morbidities, and factors related to the patients’ PC history.
"The overall feeling is that ADT does not provide protection against SARS−COV-2 infection, except perhaps in the early phases of PC, and that mCRPC patients who develop SARS−COV-2 infection have a poorer prognosis than patients in earlier stages of the disease. Nevertheless, larger prospective population studies are warranted in order to clarify the relationship between ADT and the severity of SARS−COV-2 infection in patients with PC."
-Patrick
[1] Full text:
sciencedirect.com/science/a...
Severe acute respiratory syndrome coronavirus 2 infection in patients with prostate cancer: A critical review
OrazioCaffoaMarcoMessinabAntonelloVecciaaStefaniaKinspergheraFrancescaMainesaCarloMessinab
a
Medical OncologyDepartments of Santa Chiara Hospital, Trento, Italy
b
Medical Oncology Departments of Civic Hospital, Palermo, Italy
Received 11 August 2021, Revised 30 September 2021, Accepted 1 October 2021, Available online 6 October 2021.
Highlights
•
Androgen deprivation therapy (ADT) could influence COVID-19.
•
ADT is the backbone of prostate cancer (PC) treatment.
•
Several reports evaluated the infection outcomes in PC patients.
•
We recorded 14 reports aimed to assess the relationship ADT/COVID19.
•
An incomplete evaluation of all interfering factors did not allow conclusions.
Abstract
Real-world data suggest a possible interplay between androgen deprivation therapy (ADT) and susceptibility to and the severity of SARS-CoV-2 infection. As ADT is the backbone of prostate cancer treatment, various authors have evaluated different patient cohorts but the evidence provided is conflicting. The aim of this review is to assess the available publications concerning the role of ADT in preventing or reducing the severity of SARS-CoV-2 infection. After a literature search we identified four full papers, five letters, and four meeting abstracts, but these used different search methods and the quality of the evidence varied. They frequently had different endpoints, did not report the status of the prostate cancer patients and evaluated heterogeneous populations. The available data do not support the view that ADT protects against SARS-CoV-2 infection. Larger and more precise studies are warranted, considering variables that affect infection outcomes as these significantly influence the reliability of the findings.
Importance of ADT
